Hasil Pencarian - Massimo Di Nicola

  • Menampilkan 1 - 14 hasil dari 14
Perbaiki Hasil
  1. 1
    The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells

    The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor... oleh Roberta Zappasodi, Massimo Di Nicola, Carmelo Carlo-Stella, Roberta Mortarini, Alessandra Molla, Claudia Vegetti, Salvatore Albani, Andrea Anichini, Alessandro M. Gianni

    Diterbitkan 2008-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Stabilization of c-KIT G-Quadruplex DNA Structures by the RNA Polymerase I Inhibitors BMH-21 and BA-41

    Stabilization of c-KIT G-Quadruplex DNA Structures by the RNA Polymerase I Inhibitors BMH-21 and BA-41 oleh Stefania Mazzini, Raimundo Gargallo, Loana Musso, Francesca De Santis, Anna Aviñó, Leonardo Scaglioni, Ramon Eritja, Massimo Di Nicola, Franco Zunino, Annabella Amatulli, Sabrina Dallavalle

    Diterbitkan 2019-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy

    A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy oleh Alessandro Satta, Giulia Grazia, Francesco Caroli, Barbara Frigerio, Massimo Di Nicola, Francesco Raspagliesi, Delia Mezzanzanica, Nadia Zaffaroni, Alessandro Massimo Gianni, Andrea Anichini, Mariangela Figini

    Diterbitkan 2019-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities

    SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities oleh Sabina Sangaletti, Giovanna Talarico, Claudia Chiodoni, Barbara Cappetti, Laura Botti, Paola Portararo, Alessandro Gulino, Francesca Maria Consonni, Antonio Sica, Antonio Sica, Giovanni Randon, Massimo Di Nicola, Claudio Tripodo, Mario P. Colombo

    Diterbitkan 2019-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy

    ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy oleh Hendrik-Tobias Arkenau, Jean-Yves Douillard, Nicolas Penel, Teresa Amaral, Ahmad Awada, Emiliano Calvo, Viktor Gruenwald, Jose Luis Perez-Gracia, Ruth Vera, Martijn P Lolkema, Gyorgy Bodoky, Massimo Di Nicola, Miguel F Sanmamed

    Diterbitkan 2020-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade

    Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade oleh Licia Rivoltini, Chiara Camisaschi, Giovanni Fucà, Biagio Paolini, Barbara Vergani, Valeria Beretta, Silvia Damian, Matteo Duca, Sara Cresta, Michele Magni, Biagio Eugenio Leone, Chiara Castelli, Filippo de Braud, Francesca De Santis, Massimo Di Nicola

    Diterbitkan 2024-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    A combination of extracellular matrix‐ and interferon‐associated signatures identifies high‐grade breast cancers with poor prognosis

    A combination of extracellular matrix‐ and interferon‐associated signatures identifies high‐grade breast cancers with poor prognosis oleh Mara Lecchi, Paolo Verderio, Vera Cappelletti, Francesca De Santis, Biagio Paolini, Melissa Monica, Sabina Sangaletti, Serenella Maria Pupa, Marilena Valeria Iorio, Giulia Bianchi, Massimiliano Gennaro, Giovanni Fucà, Filippo De Braud, Elda Tagliabue, Massimo Di Nicola

    Diterbitkan 2021-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells

    Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells oleh Filippo de Braud, Francesca De Santis, Roberta Zappasodi, Massimo Di Nicola, Margherita Ambrosini, Michele Magni, Luca Agnelli, Silvia Brich, Francesco Sgambelluri, Roberta Mortarini, Serenella M Pupa, Liliana Devizzi, Paola Matteucci, Antonello Cabras, Andrea Anichini, Alessandro M Gianni

    Diterbitkan 2021-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation

    Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation oleh Peter Dreger, Paolo Pedrazzoli, Salvatore Siena, Christoph E Heilig, Stefan Fröhling, Massimo Di Nicola, Manuela Badoglio, Myriam Labopin, Simona Secondino, Jürgen Heinz, Emmanuelle Nicolas-Virelizier, Didier Blaise, Clément Korenbaum, Armando Santoro, Mareike Verbeek, William Krüger, Jakob R Passweg, Jose Rifón, Ulrike Koehl, Christian Chabannon

    Diterbitkan 2020-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study.

    Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study. oleh Serena Di Cosimo, Nicla La Verde, Anna Moretti, Marina Elena Cazzaniga, Daniele Generali, Giulia Valeria Bianchi, Luigi Mariani, Valter Torri, Flavio Crippa, Biagio Paolini, Gianfranco Scaperrotta, Maria Carmen De Santis, Massimo Di Nicola, Giovanni Apolone, Alessandro Gulino, Claudio Tripodo, Mario Paolo Colombo, Secondo Folli, Filippo de Braud

    Diterbitkan 2019-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

    A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previous... oleh Marek Trnĕný, Gregor Verhoef, Martin JS Dyer, Dina Ben Yehuda, Caterina Patti, Miguel Canales, Andrés Lopez, Farrukh T Awan, Paul G Montgomery, Andrea Janikova, Anna M Barbui, Kazimierz Sulek, Maria J Terol, John Radford, Anna Guidetti, Massimo Di Nicola, Laure Siraudin, Laurence Hatteville, Sandrine Schwab, Corina Oprea, Alessandro M Gianni

    Diterbitkan 2018-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    520 Preliminary biomarker and pharmacodynamic (PD) activity of the TGFβ inhibitor SAR439459, alone or in combination with cemiplimab, in a phase 1 clinical study in patients with advanced solid tumors

    520 Preliminary biomarker and pharmacodynamic (PD) activity of the TGFβ inhibitor SAR439459, alone or in combination with cemiplimab, in a phase 1 clinical study in patients with a... oleh Rui Wang, Ivan Borbath, Patrícia Martin, Armando Santoro, Bernard Doger, Elena Garralda, Oliver Bechter, Giovanni Abbadessa, Debbie Robbrecht, Grob Jean-Jacques, Butler Marcus, Cheng Tina, Bennouna Jaafar, Massimo Di Nicola, Alejo Rodriguez -Vida, Dirk Schadendof, Brigitte Demers, Amele Amrate, Tun Tun Lin, Manisha Brahmachary, Joon Sange Lee, Joachim Theilhaber, Rob Pomponio

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Biomarker and pharmacodynamic activity of the transforming growth factor‐beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors

    Biomarker and pharmacodynamic activity of the transforming growth factor‐beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical stu... oleh Debbie Robbrecht, Jean‐Jacques Grob, Oliver Bechter, Matteo Simonelli, Bernard Doger, Ivan Borbath, Marcus O. Butler, Tina Cheng, Patricia Martin Romano, Elvire Pons‐Tostivint, Massimo Di Nicola, Giuseppe Curigliano, Min‐Hee Ryu, Alejo Rodriguez‐Vida, Dirk Schadendorf, Elena Garralda, Giovanni Abbadessa, Brigitte Demers, Amele Amrate, Hong Wang, Joon Sang Lee, Robert Pomponio, Rui Wang

    Diterbitkan 2024-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden

    Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden oleh Alexandra Leary, Paolo A Ascierto, Michele Maio, Georgia Kollia, Jennifer Friedmann, Marina Tschaika, Patrick Schöffski, Jonathan Baden, Neeltje Steeghs, Parul Doshi, Massimo Di Nicola, Jean-Pierre Delord, Iwona Lugowska, Mauricio Burotto, David S P Tan, Anthony Gonçalves, Michael Schenker, Ning Huang, Tudor-Eliade Ciuleanu, Martin Richardet, Lorena Lupinacci, Julieta Grasselli, Jacqueline Vuky, Somasekhar Konduru, Sai Vikram Vemula, Ruta Slepetis, Misena Pacius, Quyen Duong

    Diterbitkan 2024-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: